While big pharma chases blockbuster drugs, VISUfarma quietly dominates the €5B+ ocular surface disease market with a focused portfolio of high-margin medical devices and supplements. They aren't building a generalist platform—they are the 'Eye Health Company,' and that laser focus is their competitive moat.

"They aren't fighting for the general dry eye patient; they are capturing the specific, high-intent searcher looking for 'VisuFly' and 'Xailin Night'—brand-led demand that converts."

The tech stack (WordPress, jQuery, Tailwind) suggests a pragmatic, cost-effective approach rather than a bleeding-edge digital experience. This isn't a consumer tech startup; it's a medical B2B2C company where the website serves as a trust anchor for doctors and a direct channel for informed patients. The lack of a Trustpilot score or public funding rounds suggests they are bootstrapped or privately held, prioritizing sustainable growth over hype cycles.

• Vertical Integration: Managing supply chain (VP Diego Dirube) likely ensures margin control on physical products.
• Brand Authority: 'VisuFly' and 'Xailin' are becoming category keywords, bypassing generic search terms.
• Regulatory Navigation: Operating in 'Digital Health' while selling physical medical devices requires complex compliance handling.